---
document_datetime: 2025-12-02 05:25:01
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/lenalidomide-accord.html
document_name: lenalidomide-accord.html
version: success
processing_time: 0.101236
conversion_datetime: 2025-12-24 03:23:16.12733
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Lenalidomide Accord

[RSS](/en/individual-human-medicine.xml/66452)

##### Authorised

This medicine is authorised for use in the European Union

lenalidomide Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Lenalidomide Accord](#news-on)
- [More information on Lenalidomide Accord](#more-information-on-lenalidomide-accord-1325)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Lenalidomide Accord is a medicine used for the treatment of multiple myeloma (cancer of a type of white blood cells called plasma cells) and follicular lymphoma (cancer of another type of white blood cells called B lymphocytes).

In multiple myeloma, Lenalidomide Accord is used:

- in adults who have had a stem cell transplant (a procedure where the patient's bone marrow is cleared of cells and replaced by stem cells from a donor);
- in adults with previously untreated (newly diagnosed) multiple myeloma, who cannot have a stem cell transplant. It is used in combination with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone;
- in adults whose disease has been treated at least once. It is used in combination with dexamethasone.

In follicular lymphoma, Lenalidomide Accord is used in adults who have already been treated for their disease. It is used with the medicine rituximab.

Lenalidomide Accord is a 'generic medicine'. This means that Lenalidomide Accord contains the same active substance and works in the same way as a 'reference medicine' already authorised in the EU called Revlimid. For more information on generic medicines, see the question-and-answer document below.

Expand section

Collapse section

## How is Lenalidomide Accord used?

Lenalidomide Accord is available as capsules of various strengths to be taken by mouth. The medicine can only be obtained with a prescription and treatment must be monitored by doctors who have experience in the use of cancer medicines.

Treatment is given in cycles, with Lenalidomide Accord being used once a day on certain days of the cycles. Treatment cycles are continued until the disease is no longer being controlled or side effects become unacceptable. The dose of Lenalidomide Accord depends on the disease it is being used for, the patient's overall health and blood test results. The dose may need to be reduced or treatment interrupted in case of certain side effects.

For more information about using Lenalidomide Accord, see the package leaflet or contact your doctor or pharmacist.

## How does Lenalidomide Accord work?

The active substance in Lenalidomide Accord, lenalidomide, is an immunomodulator. This means that it affects the activity of the immune system (the body's natural defences). Lenalidomide works in several ways: it blocks the development of abnormal cells, prevents the growth of blood vessels within tumours and also stimulates specialised cells of the immune system to attack the abnormal cells.

## How has Lenalidomide Accord been studied?

Studies on the benefits and risks of the active substance in the authorised uses have already been carried out with the reference medicine, Revlimid, and do not need to be repeated for Lenalidomide Accord.

As for every medicine, the company provided studies on the quality of Lenalidomide Accord. The company also carried out a study that showed that it is 'bioequivalent' to the reference medicine. Two medicines are bioequivalent when they produce the same levels of the active substance in the body and are therefore expected to have the same effect.

## What are the benefits and risks of Lenalidomide Accord?

Because Lenalidomide Accord is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.

## Why is Lenalidomide Accord authorised in the EU?

The European Medicines Agency concluded that, in accordance with EU requirements, Lenalidomide Accord has been shown to have comparable quality and to be bioequivalent to Revlimid. Therefore, the Agency's view was that, as for Revlimid, the benefit of Lenalidomide Accord outweighs the identified risk and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Lenalidomide Accord?

The company that markets Lenalidomide Accord will provide a letter and educational kits for healthcare professionals, and brochures for patients, explaining that the medicine can be harmful to the unborn child and detailing the steps that need to be taken for the medicine to be used safely. It will also supply cards to patients about the safety measures patients should take.

The company has also set up a pregnancy prevention programme in each Member State and will collect information on the medicine's use outside its authorised uses. The boxes containing Lenalidomide Accord capsules also include a warning stating that lenalidomide can be harmful to the unborn child.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Lenalidomide Accord have also been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Lenalidomide Accord are continuously monitored. Side effects reported with Lenalidomide Accord are carefully evaluated and any necessary action taken to protect patients.

## Other information about Lenalidomide Accord

Lenalidomide Accord received a marketing authorisation valid throughout the EU on 20 September 2018.

Lenalidomide Accord : EPAR - Medicine overview

Reference Number: EMA/90018/2021

English (EN) (144.75 KB - PDF)

**First published:** 12/10/2018

**Last updated:** 17/02/2021

[View](/en/documents/overview/lenalidomide-accord-epar-medicine-overview_en.pdf)

[Other languages (21)](#file-language-dropdown-63)

български (BG) (168.57 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

17/02/2021

[View](/bg/documents/overview/lenalidomide-accord-epar-medicine-overview_bg.pdf)

español (ES) (145.31 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

17/02/2021

[View](/es/documents/overview/lenalidomide-accord-epar-medicine-overview_es.pdf)

čeština (CS) (167.23 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

17/02/2021

[View](/cs/documents/overview/lenalidomide-accord-epar-medicine-overview_cs.pdf)

dansk (DA) (144.81 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

17/02/2021

[View](/da/documents/overview/lenalidomide-accord-epar-medicine-overview_da.pdf)

Deutsch (DE) (148.56 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

17/02/2021

[View](/de/documents/overview/lenalidomide-accord-epar-medicine-overview_de.pdf)

eesti keel (ET) (133.61 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

17/02/2021

[View](/et/documents/overview/lenalidomide-accord-epar-medicine-overview_et.pdf)

ελληνικά (EL) (167.87 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

17/02/2021

[View](/el/documents/overview/lenalidomide-accord-epar-medicine-overview_el.pdf)

français (FR) (146.83 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

17/02/2021

[View](/fr/documents/overview/lenalidomide-accord-epar-medicine-overview_fr.pdf)

hrvatski (HR) (164.65 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

17/02/2021

[View](/hr/documents/overview/lenalidomide-accord-epar-medicine-overview_hr.pdf)

italiano (IT) (143.8 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

17/02/2021

[View](/it/documents/overview/lenalidomide-accord-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (183.8 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

17/02/2021

[View](/lv/documents/overview/lenalidomide-accord-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (166.39 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

17/02/2021

[View](/lt/documents/overview/lenalidomide-accord-epar-medicine-overview_lt.pdf)

magyar (HU) (166.1 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

17/02/2021

[View](/hu/documents/overview/lenalidomide-accord-epar-medicine-overview_hu.pdf)

Malti (MT) (168.71 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

17/02/2021

[View](/mt/documents/overview/lenalidomide-accord-epar-medicine-overview_mt.pdf)

Nederlands (NL) (144.98 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

17/02/2021

[View](/nl/documents/overview/lenalidomide-accord-epar-medicine-overview_nl.pdf)

polski (PL) (168.71 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

17/02/2021

[View](/pl/documents/overview/lenalidomide-accord-epar-medicine-overview_pl.pdf)

português (PT) (145.67 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

17/02/2021

[View](/pt/documents/overview/lenalidomide-accord-epar-medicine-overview_pt.pdf)

română (RO) (163.13 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

17/02/2021

[View](/ro/documents/overview/lenalidomide-accord-epar-medicine-overview_ro.pdf)

slovenčina (SK) (166.46 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

17/02/2021

[View](/sk/documents/overview/lenalidomide-accord-epar-medicine-overview_sk.pdf)

slovenščina (SL) (164.21 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

17/02/2021

[View](/sl/documents/overview/lenalidomide-accord-epar-medicine-overview_sl.pdf)

Suomi (FI) (142.63 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

17/02/2021

[View](/fi/documents/overview/lenalidomide-accord-epar-medicine-overview_fi.pdf)

Lenalidomide Accord : EPAR - Risk management plan

English (EN) (1.01 MB - PDF)

**First published:** 02/06/2021

**Last updated:** 02/07/2024

[View](/en/documents/rmp-summary/lenalidomide-accord-epar-risk-management-plan_en.pdf)

## Product information

Lenalidomide Accord : EPAR - Product information

English (EN) (1.05 MB - PDF)

**First published:** 12/10/2018

**Last updated:** 02/07/2024

[View](/en/documents/product-information/lenalidomide-accord-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-78)

български (BG) (1.2 MB - PDF)

**First published:**

12/10/2018

**Last updated:**

02/07/2024

[View](/bg/documents/product-information/lenalidomide-accord-epar-product-information_bg.pdf)

español (ES) (942.2 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

02/07/2024

[View](/es/documents/product-information/lenalidomide-accord-epar-product-information_es.pdf)

čeština (CS) (929.45 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

02/07/2024

[View](/cs/documents/product-information/lenalidomide-accord-epar-product-information_cs.pdf)

dansk (DA) (1.18 MB - PDF)

**First published:**

12/10/2018

**Last updated:**

02/07/2024

[View](/da/documents/product-information/lenalidomide-accord-epar-product-information_da.pdf)

Deutsch (DE) (1.34 MB - PDF)

**First published:**

12/10/2018

**Last updated:**

02/07/2024

[View](/de/documents/product-information/lenalidomide-accord-epar-product-information_de.pdf)

eesti keel (ET) (981.5 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

02/07/2024

[View](/et/documents/product-information/lenalidomide-accord-epar-product-information_et.pdf)

ελληνικά (EL) (1.39 MB - PDF)

**First published:**

12/10/2018

**Last updated:**

02/07/2024

[View](/el/documents/product-information/lenalidomide-accord-epar-product-information_el.pdf)

français (FR) (1.08 MB - PDF)

**First published:**

12/10/2018

**Last updated:**

02/07/2024

[View](/fr/documents/product-information/lenalidomide-accord-epar-product-information_fr.pdf)

hrvatski (HR) (1.4 MB - PDF)

**First published:**

12/10/2018

**Last updated:**

02/07/2024

[View](/hr/documents/product-information/lenalidomide-accord-epar-product-information_hr.pdf)

íslenska (IS) (1.24 MB - PDF)

**First published:**

12/10/2018

**Last updated:**

02/07/2024

[View](/is/documents/product-information/lenalidomide-accord-epar-product-information_is.pdf)

italiano (IT) (1.3 MB - PDF)

**First published:**

12/10/2018

**Last updated:**

02/07/2024

[View](/it/documents/product-information/lenalidomide-accord-epar-product-information_it.pdf)

latviešu valoda (LV) (1.22 MB - PDF)

**First published:**

12/10/2018

**Last updated:**

02/07/2024

[View](/lv/documents/product-information/lenalidomide-accord-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.52 MB - PDF)

**First published:**

12/10/2018

**Last updated:**

02/07/2024

[View](/lt/documents/product-information/lenalidomide-accord-epar-product-information_lt.pdf)

magyar (HU) (1.33 MB - PDF)

**First published:**

12/10/2018

**Last updated:**

02/07/2024

[View](/hu/documents/product-information/lenalidomide-accord-epar-product-information_hu.pdf)

Malti (MT) (1.6 MB - PDF)

**First published:**

12/10/2018

**Last updated:**

02/07/2024

[View](/mt/documents/product-information/lenalidomide-accord-epar-product-information_mt.pdf)

Nederlands (NL) (1.32 MB - PDF)

**First published:**

12/10/2018

**Last updated:**

02/07/2024

[View](/nl/documents/product-information/lenalidomide-accord-epar-product-information_nl.pdf)

norsk (NO) (1.22 MB - PDF)

**First published:**

12/10/2018

**Last updated:**

02/07/2024

[View](/no/documents/product-information/lenalidomide-accord-epar-product-information_no.pdf)

polski (PL) (1.4 MB - PDF)

**First published:**

12/10/2018

**Last updated:**

02/07/2024

[View](/pl/documents/product-information/lenalidomide-accord-epar-product-information_pl.pdf)

português (PT) (1.3 MB - PDF)

**First published:**

12/10/2018

**Last updated:**

02/07/2024

[View](/pt/documents/product-information/lenalidomide-accord-epar-product-information_pt.pdf)

română (RO) (1.36 MB - PDF)

**First published:**

12/10/2018

**Last updated:**

02/07/2024

[View](/ro/documents/product-information/lenalidomide-accord-epar-product-information_ro.pdf)

slovenčina (SK) (1.38 MB - PDF)

**First published:**

12/10/2018

**Last updated:**

02/07/2024

[View](/sk/documents/product-information/lenalidomide-accord-epar-product-information_sk.pdf)

slovenščina (SL) (1.26 MB - PDF)

**First published:**

12/10/2018

**Last updated:**

02/07/2024

[View](/sl/documents/product-information/lenalidomide-accord-epar-product-information_sl.pdf)

Suomi (FI) (1.26 MB - PDF)

**First published:**

12/10/2018

**Last updated:**

02/07/2024

[View](/fi/documents/product-information/lenalidomide-accord-epar-product-information_fi.pdf)

svenska (SV) (1.24 MB - PDF)

**First published:**

12/10/2018

**Last updated:**

02/07/2024

[View](/sv/documents/product-information/lenalidomide-accord-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** IB/0025/G 26/06/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Lenalidomide Accord : EPAR - All authorised presentations

English (EN) (229.77 KB - PDF)

**First published:** 12/10/2018

**Last updated:** 07/05/2021

[View](/en/documents/all-authorised-presentations/lenalidomide-accord-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-936)

български (BG) (104.05 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

07/05/2021

[View](/bg/documents/all-authorised-presentations/lenalidomide-accord-epar-all-authorised-presentations_bg.pdf)

español (ES) (94.86 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

07/05/2021

[View](/es/documents/all-authorised-presentations/lenalidomide-accord-epar-all-authorised-presentations_es.pdf)

čeština (CS) (98.59 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

07/05/2021

[View](/cs/documents/all-authorised-presentations/lenalidomide-accord-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (97.91 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

07/05/2021

[View](/da/documents/all-authorised-presentations/lenalidomide-accord-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (96.42 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

07/05/2021

[View](/de/documents/all-authorised-presentations/lenalidomide-accord-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (97.3 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

07/05/2021

[View](/et/documents/all-authorised-presentations/lenalidomide-accord-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (101.88 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

07/05/2021

[View](/el/documents/all-authorised-presentations/lenalidomide-accord-epar-all-authorised-presentations_el.pdf)

français (FR) (97.61 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

07/05/2021

[View](/fr/documents/all-authorised-presentations/lenalidomide-accord-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (98.58 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

07/05/2021

[View](/hr/documents/all-authorised-presentations/lenalidomide-accord-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (98.33 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

07/05/2021

[View](/is/documents/all-authorised-presentations/lenalidomide-accord-epar-all-authorised-presentations_is.pdf)

italiano (IT) (94.27 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

07/05/2021

[View](/it/documents/all-authorised-presentations/lenalidomide-accord-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (102.12 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

07/05/2021

[View](/lv/documents/all-authorised-presentations/lenalidomide-accord-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (100.75 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

07/05/2021

[View](/lt/documents/all-authorised-presentations/lenalidomide-accord-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (99.9 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

07/05/2021

[View](/hu/documents/all-authorised-presentations/lenalidomide-accord-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (102.62 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

07/05/2021

[View](/mt/documents/all-authorised-presentations/lenalidomide-accord-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (93.88 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

07/05/2021

[View](/nl/documents/all-authorised-presentations/lenalidomide-accord-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (97.14 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

07/05/2021

[View](/no/documents/all-authorised-presentations/lenalidomide-accord-epar-all-authorised-presentations_no.pdf)

polski (PL) (99.18 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

07/05/2021

[View](/pl/documents/all-authorised-presentations/lenalidomide-accord-epar-all-authorised-presentations_pl.pdf)

português (PT) (94.41 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

07/05/2021

[View](/pt/documents/all-authorised-presentations/lenalidomide-accord-epar-all-authorised-presentations_pt.pdf)

română (RO) (99.52 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

07/05/2021

[View](/ro/documents/all-authorised-presentations/lenalidomide-accord-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (100.7 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

07/05/2021

[View](/sk/documents/all-authorised-presentations/lenalidomide-accord-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (96.5 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

07/05/2021

[View](/sl/documents/all-authorised-presentations/lenalidomide-accord-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (94.7 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

07/05/2021

[View](/fi/documents/all-authorised-presentations/lenalidomide-accord-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (97.19 KB - PDF)

**First published:**

12/10/2018

**Last updated:**

07/05/2021

[View](/sv/documents/all-authorised-presentations/lenalidomide-accord-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Lenalidomide Accord Active substance lenalidomide International non-proprietary name (INN) or common name lenalidomide Therapeutic area (MeSH) Multiple Myeloma Anatomical therapeutic chemical (ATC) code L04AX04

### Pharmacotherapeutic group

Immunosuppressants

### Therapeutic indication

**Multiple myeloma**

Lenalidomide Accord as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4.2) is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant.

Lenalidomide Accord in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy.

**Follicular lymphoma** Lenalidomide Accord in combination with rituximab (anti-CD20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (Grade 1 - 3a).

## Authorisation details

EMA product number EMEA/H/C/004857

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Accord Healthcare S.L.U.

Edificio Este Planta 6a World Trade Center Moll De Barcelona S/n 08039 Barcelona SPAIN

Opinion adopted 26/07/2018 Marketing authorisation issued 20/09/2018 Revision 12

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Lenalidomide Accord : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (178.45 KB - PDF)

**First published:** 15/04/2019

**Last updated:** 02/07/2024

[View](/en/documents/procedural-steps-after/lenalidomide-accord-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Lenalidomide Accord-H-C-PSUSA-00001838-202012 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/618753/2021

English (EN) (122.39 KB - PDF)

**First published:** 03/11/2021

[View](/en/documents/scientific-conclusion/lenalidomide-accord-h-c-psusa-00001838-202012-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Lenalidomide Accord-H-C-PSUSA-00001838-201912 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Adopted

Reference Number: EMA/517770/2020

English (EN) (131.26 KB - PDF)

**First published:** 05/10/2020

[View](/en/documents/scientific-conclusion/lenalidomide-accord-h-c-psusa-00001838-201912-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

## Initial marketing authorisation documents

Lenalidomide Accord : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/563114/2018

English (EN) (1.24 MB - PDF)

**First published:** 12/10/2018

[View](/en/documents/assessment-report/lenalidomide-accord-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Lenalidomide Accord

Adopted

Reference Number: EMA/CHMP/475938/2018

English (EN) (71.59 KB - PDF)

**First published:** 27/07/2018

**Last updated:** 27/07/2018

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-lenalidomide-accord_en.pdf)

#### News on Lenalidomide Accord

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 July 2018](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-23-26-july-2018) 27/07/2018

#### More information on Lenalidomide Accord

Questions and answers on generic medicines

Reference Number: EMA/393905/2006 Rev. 2

English (EN) (66.45 KB - PDF)

**First published:** 09/07/2007

**Last updated:** 07/12/2012

[View](/en/documents/other/questions-and-answers-generic-medicines_en.pdf)

[Other languages (22)](#file-language-dropdown-211)

български (BG) (93.16 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/bg/documents/other/questions-and-answers-generic-medicines_bg.pdf)

español (ES) (68.3 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/es/documents/other/questions-and-answers-generic-medicines_es.pdf)

čeština (CS) (87.71 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/cs/documents/other/questions-and-answers-generic-medicines_cs.pdf)

dansk (DA) (66.79 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/da/documents/other/questions-and-answers-generic-medicines_da.pdf)

Deutsch (DE) (67.55 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/de/documents/other/questions-and-answers-generic-medicines_de.pdf)

eesti keel (ET) (65.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/et/documents/other/questions-and-answers-generic-medicines_et.pdf)

ελληνικά (EL) (91.29 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/el/documents/other/questions-and-answers-generic-medicines_el.pdf)

français (FR) (68.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fr/documents/other/questions-and-answers-generic-medicines_fr.pdf)

hrvatski (HR) (87.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hr/documents/other/questions-and-answers-generic-medicines_hr.pdf)

italiano (IT) (67.62 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/it/documents/other/questions-and-answers-generic-medicines_it.pdf)

latviešu valoda (LV) (111.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lv/documents/other/questions-and-answers-generic-medicines_lv.pdf)

lietuvių kalba (LT) (86.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lt/documents/other/questions-and-answers-generic-medicines_lt.pdf)

magyar (HU) (85.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hu/documents/other/questions-and-answers-generic-medicines_hu.pdf)

Malti (MT) (89.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/mt/documents/other/questions-and-answers-generic-medicines_mt.pdf)

Nederlands (NL) (66.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/nl/documents/other/questions-and-answers-generic-medicines_nl.pdf)

polski (PL) (88.51 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pl/documents/other/questions-and-answers-generic-medicines_pl.pdf)

português (PT) (68.32 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pt/documents/other/questions-and-answers-generic-medicines_pt.pdf)

română (RO) (86.9 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/ro/documents/other/questions-and-answers-generic-medicines_ro.pdf)

slovenčina (SK) (87.73 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sk/documents/other/questions-and-answers-generic-medicines_sk.pdf)

slovenščina (SL) (84.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sl/documents/other/questions-and-answers-generic-medicines_sl.pdf)

Suomi (FI) (66.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fi/documents/other/questions-and-answers-generic-medicines_fi.pdf)

svenska (SV) (67.11 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sv/documents/other/questions-and-answers-generic-medicines_sv.pdf)

#### Topics

- [Generic and hybrid medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A54)
- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 02/07/2024

## Share this page

[Back to top](#main-content)